BiomX Inc. (PHGE)Stock Price & Financial Statements
AboutBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Show more
- Revenue $0
- EBITDA -$37M -38.8%
- Net Income -$18M +32.3%
- EPS (Diluted) -1.47 +71.2%
- Gross Margin -
- EBITDA Margin -
- Operating Margin -
- Net Margin -
- ROE -130.21% +40.0%
- ROIC -305.15% +9.4%
- Debt/Equity 0.40 -91.9%
- Interest Coverage -14.01 -21.6%
Key Insights
Based on financial data analysisStrengths
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓High quality earnings: Operating CF exceeds net income
Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 3427.6x book value
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM-
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-181.44%
EPS CAGR
10Y-
5Y-
3Y-
TTM96.49%
ROCE
10Y Avg-69.31%
5Y Avg-82.93%
3Y Avg-106.53%
Latest-159.88%
Peer Comparison
Microbiome and Phage Therapeutics| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 ELABPMGC Holdings Inc. | 23.88K | 1.05 | -0.00 | 44.07% | -253.14% | -78.44% | ||
 TOVXTheriva Biologics, Inc. | 252.1K | 0.19 | -0.01 | -388.69% | 0.08 | |||
 AZTRAzitra, Inc. | 2.03M | 0.19 | -0.08 | -100% | -0.29% | 0.11 | ||
 EVGNEvogene Ltd. | 7.31M | 0.84 | -0.29 | 50.9% | -52.33% | -15.93% | 0.87 | |
 SYBXSynlogic, Inc. | 7.02M | 0.60 | -0.31 | -99.76% | -2919.88% | -31.25% | ||
 MCRBSeres Therapeutics, Inc. | 80.02M | 9.13 | -0.48 | 15.37% | 12.34% | 6.65 | ||
PHGEBiomX Inc. | 82.77B | 6.30 | -4.29 | -356.43% | 0.40 | |||
 ARMPArmata Pharmaceuticals, Inc. | 419.83M | 11.61 | -22.19 | 14.24% | -9.28% |
Compare PHGE vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 95K | 210K | 0 | 0 | 0 | 0 | 871K | 1.8M |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -95K | -210K | 0 | 0 | 0 | 0 | -871K | -1.8M |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -121.05% | 100% | - | - | - | - | -107% |
| Operating Expenses | 7.28M | 12.93M | 22.21M | 30.26M | 35.46M | 27.22M | 26.81M | 37.22M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.54M | 3.36M | 8.72M | 9.99M | 11.27M | 9.46M | 7.78M | 11.78M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 4.74M | 9.57M | 13.96M | 21.61M | 22.68M | 16.24M | 19.04M | 24.66M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -466K | -1.34M | 1.52M | 1.52M | 0 | 785K |
| Operating Income | -7.37M | -13.14M | -22.21M | -30.26M | -35.46M | -27.22M | -27.68M | -39.03M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -78.26% | -68.99% | -36.25% | -17.2% | 23.24% | -1.71% | -40.97% |
| EBITDA | -7.28M | -12.93M | -21.89M | -29.6M | -32.9M | -24.7M | -26.81M | -37.22M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -77.7% | -69.28% | -35.21% | -11.15% | 24.92% | -8.56% | -38.82% |
| D&A (Non-Cash Add-back) | 95K | 210K | 318K | 662K | 2.56M | 2.52M | 871K | 1.8M |
| EBIT | -6.43M | -12.72M | -22.21M | -30.26M | -35.46M | -26.18M | -23.69M | -14.93M |
| Net Interest Income | 0 | 0 | 857K | 634K | -697K | -1.17M | -1.28M | -1.74M |
| Interest Income | -21K | 0 | 921K | 641K | 2K | 902K | 1.12M | 1.05M |
| Interest Expense | 0 | 0 | 64K | 7K | 699K | 2.07M | 2.4M | 2.79M |
| Other Income/Expense | 939K | 421K | 1.64M | 172K | -697K | -1.03M | 1.54M | 21.31M |
| Pretax Income | -6.43M | -12.72M | -20.56M | -30.09M | -36.16M | -28.25M | -26.15M | -17.71M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 67K | 65K | 23K | 13K |
| Effective Tax Rate % | 100% | 100% | 100% | 100% | 100.19% | 100.23% | 100.09% | 100.07% |
| Net Income | -6.43M | -12.72M | -20.56M | -30.09M | -36.23M | -28.32M | -26.17M | -17.73M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -97.73% | -61.66% | -46.31% | -20.41% | 21.83% | 7.59% | 32.26% |
| Net Income (Continuing) | -6.43M | -12.72M | -20.56M | -30.09M | -36.23M | -28.32M | -26.17M | -17.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.27 | -6.46 | -0.84 | -1.30 | -13.93 | -9.49 | -5.10 | -1.47 |
| EPS Growth % | - | -97.55% | 87% | -54.76% | -971.54% | 31.87% | 46.26% | 71.18% |
| EPS (Basic) | -3.27 | -6.46 | -0.84 | -1.30 | -13.93 | -9.49 | -5.10 | -1.47 |
| Diluted Shares Outstanding | 19.68M | 20.02M | 22.63M | 23.06M | 26.01M | 29.85M | 51.33M | 13.14B |
| Basic Shares Outstanding | 19.68M | 20.02M | 22.63M | 23.06M | 26.01M | 29.85M | 51.33M | 69.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Balance Sheet
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.47M | 39.89M | 84.53M | 60.67M | 66.64M | 36.88M | 17.63M | 20.52M |
| Cash & Short-Term Investments | 8.15M | 39.66M | 82.41M | 56.33M | 62.1M | 33.33M | 14.91M | 17.81M |
| Cash Only | 6.99M | 8.6M | 72.41M | 36.48M | 62.1M | 31.33M | 14.91M | 17.81M |
| Short-Term Investments | 1.15M | 31.05M | 10M | 19.85M | 0 | 2M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 244K | 0 | 888K | 567K | 574K | 1.17M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | -29K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 50K | 2.25M | 1.4M | 1.49M | 1.52M | 254K |
| Total Non-Current Assets | 5.52M | 5.44M | 7.59M | 9.7M | 11.35M | 8.65M | 7.4M | 22.71M |
| Property, Plant & Equipment | 960K | 887K | 3.03M | 6.66M | 9.83M | 8.65M | 7.4M | 10.5M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 4.56M | 4.56M | 3.04M | 1.52M | 0 | 0 | 12.05M |
| Long-Term Investments | 0 | 70.88M | 0 | 0 | 0 | 0 | 0 | 161K |
| Other Non-Current Assets | 4.56M | -70.88M | 5K | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 13.99M | 45.33M | 92.12M | 70.36M | 77.99M | 45.53M | 25.03M | 43.23M |
| Asset Turnover | - | - | - | - | - | - | - | - |
| Asset Growth % | - | 224.02% | 103.22% | -23.62% | 10.84% | -41.62% | -45.03% | 72.73% |
| Total Current Liabilities | 1.46M | 1.64M | 6.22M | 7.16M | 11.04M | 7.94M | 11.18M | 8.27M |
| Accounts Payable | 1K | 56.58K | 3.25M | 2.32M | 2.79M | 820K | 1.38M | 1.88M |
| Days Payables Outstanding | 3.84 | 98.34 | - | - | - | - | 578.72 | 380.99 |
| Short-Term Debt | 40K | 0 | 375K | 0 | 0 | 4.28M | 5.79M | 0 |
| Deferred Revenue (Current) | -40K | 58K | 60K | 65K | 1.98M | 242K | 28K | 0 |
| Other Current Liabilities | 1.42M | 581K | 756K | 0 | 0 | 0 | -28K | 1.48M |
| Current Ratio | 5.81x | 24.34x | 13.58x | 8.47x | 6.03x | 4.65x | 1.58x | 2.48x |
| Quick Ratio | 5.81x | 24.35x | 13.58x | 8.47x | 6.03x | 4.65x | 1.58x | 2.48x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1M | 889K | 1.44M | 5.73M | 19.41M | 16.55M | 10.77M | 10.82M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 14.41M | 10.59M | 5.4M | 0 |
| Capital Lease Obligations | 0 | 0 | 856K | 5.03M | 4.79M | 3.8M | 3.24M | 8.45M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1M | 889K | 585K | 701K | 215K | 188K | 155K | 2.36M |
| Total Liabilities | 2.46M | 2.53M | 7.67M | 12.89M | 30.45M | 24.49M | 21.95M | 19.09M |
| Total Debt | 40K | 0 | 1.23M | 5.89M | 20.02M | 19.36M | 15.09M | 9.58M |
| Net Debt | -6.95M | -8.6M | -71.18M | -30.58M | -42.08M | -11.97M | 185K | -8.23M |
| Debt / Equity | 0.00x | - | 0.01x | 0.10x | 0.42x | 0.92x | 4.90x | 0.40x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -346.98x | -4322.57x | -50.73x | -13.16x | -11.52x | -14.01x |
| Total Equity | 11.53M | 42.8M | 84.46M | 57.47M | 47.53M | 21.04M | 3.08M | 24.15M |
| Equity Growth % | - | 271.23% | 97.31% | -31.95% | -17.29% | -55.74% | -85.36% | 683.77% |
| Book Value per Share | 0.59 | 2.14 | 3.73 | 2.49 | 1.83 | 0.70 | 0.06 | 0.00 |
| Total Shareholders' Equity | 11.53M | 42.8M | 84.46M | 57.47M | 47.53M | 21.04M | 3.08M | 24.15M |
| Common Stock | 201 | 65.75M | 2K | 2K | 2K | 2K | 3K | 6K |
| Retained Earnings | -8.89M | -21.61M | -42.17M | -72.26M | -108.48M | -136.8M | -162.97M | -180.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.02K | -21.61M | 0 | -72.26M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.1M | -11.3M | -17.58M | -24.45M | -27.57M | -29.09M | -21.29M | -36.98M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -175.71% | -55.49% | -39.09% | -12.79% | -5.51% | 26.83% | -73.72% |
| Net Income | -6.43M | -12.72M | -20.56M | -30.09M | -36.23M | -28.32M | -26.17M | -17.73M |
| Depreciation & Amortization | 95K | 210K | 318K | 2.18M | 2.56M | 2.52M | 871K | 1.8M |
| Stock-Based Compensation | 0 | 0 | 938K | 2.89M | 3.24M | 1.53M | 1.06M | 1.85M |
| Deferred Taxes | 0 | -1.22K | 0 | 0 | 24K | 0 | 0 | 0 |
| Other Non-Cash Items | 1.32M | -112K | -304K | 116K | -276K | -396K | 477K | -19.91M |
| Working Capital Changes | 928K | 367K | 2.03M | 453K | 3.1M | -4.43M | 2.48M | -2.99M |
| Change in Receivables | -225K | 187K | -100K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 407K | -228K | 3.06M | -858K | 427K | -1.98M | 556K | -3.17M |
| Cash from Investing | -2.12M | -30.04M | 19.74M | -10.86M | 16.17M | -2.11M | 1.95M | 715K |
| Capital Expenditures | -850K | -137K | -1.31M | -1.01M | -3.68M | -112K | -50K | -30K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | -112K | 0 | 0 | 0 | 4K | 0 | 0 | 663K |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -29.9M | 21.05M | 0 | 4K | 5K | 1K | 82K |
| Cash from Financing | 12.95M | 43.04M | 61.55M | 134K | 37.28M | 292K | 2.9M | 38.37M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 14.22M | 0 | -4.25M | -10.75M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | -98K | 1000K | 273K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -19K | -98K | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 57.97M | 232K | 130K | 19K | -333K | 27.83M |
| Net Change in Cash | 6.74M | 1.7M | 63.72M | -35.17M | 25.86M | -30.8M | -16.43M | 2.11M |
| Free Cash Flow | -4.95M | -11.44M | -18.89M | -25.46M | -31.25M | -29.2M | -21.34M | -37.01M |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -131.13% | -65.1% | -34.77% | -22.78% | 6.56% | 26.94% | -73.46% |
| FCF per Share | -0.25 | -0.57 | -0.83 | -1.10 | -1.20 | -0.98 | -0.42 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.89x | 0.85x | 0.81x | 0.76x | 1.03x | 0.81x | 2.09x |
| Interest Paid | 0 | 0 | 0 | 0 | 67K | 1.55M | 1.87M | 1.44M |
| Taxes Paid | 0 | 0 | 0 | 0 | 399K | 65K | 54K | 13K |
Key Ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.79% | -46.82% | -32.32% | -42.4% | -69% | -82.59% | -216.99% | -130.21% |
| Return on Invested Capital (ROIC) | - | -50.83% | -70.16% | -113% | -164.49% | -281.25% | -336.77% | -305.15% |
| Debt / Equity | 0.00x | - | 0.01x | 0.10x | 0.42x | 0.92x | 4.90x | 0.40x |
| Interest Coverage | - | - | -346.98x | -4322.57x | -50.73x | -13.16x | -11.52x | -14.01x |
| FCF Conversion | 0.64x | 0.89x | 0.85x | 0.81x | 0.76x | 1.03x | 0.81x | 2.09x |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics